{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:41:14Z","timestamp":1791276074981,"version":"4.1.0"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2013,6,28]],"date-time":"2013-06-28T00:00:00Z","timestamp":1372377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2013,6,28]],"date-time":"2013-06-28T00:00:00Z","timestamp":1372377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1038\/nrd4050","type":"journal-article","created":{"date-parts":[[2013,6,28]],"date-time":"2013-06-28T09:17:20Z","timestamp":1372411040000},"page":"595-610","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":176,"title":["Novel therapies for hepatitis C \u2014 one pill fits all?"],"prefix":"10.1038","volume":"12","author":[{"given":"Michael P.","family":"Manns","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"von Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,6,28]]},"reference":[{"key":"BFnrd4050_CR1","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/S0140-6736(78)90132-0","volume":"1","author":"E Tabor","year":"1978","unstructured":"Tabor, E. et al. Transmission of non-A, non-B hepatitis from man to chimpanzee. Lancet 1, 463\u2013466 (1978).","journal-title":"Lancet"},{"key":"BFnrd4050_CR2","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1056\/NEJM198612183152503","volume":"315","author":"JH Hoofnagle","year":"1986","unstructured":"Hoofnagle, J. H. et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N. Engl. J. Med. 315, 1575\u20131578 (1986).","journal-title":"N. Engl. J. Med."},{"key":"BFnrd4050_CR3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1126\/science.2523562","volume":"244","author":"QL Choo","year":"1989","unstructured":"Choo, Q. L. et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244, 359\u2013362 (1989). Discovery of the HCV genome.","journal-title":"Science"},{"key":"BFnrd4050_CR4","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/nature02099","volume":"426","author":"D Lamarre","year":"2003","unstructured":"Lamarre, D. et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426, 186\u2013189 (2003). First  in vivo  data in humans on an HCV DAA.","journal-title":"Nature"},{"key":"BFnrd4050_CR5","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1053\/j.gastro.2004.08.002","volume":"127","author":"H Hinrichsen","year":"2004","unstructured":"Hinrichsen, H. et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 127, 1347\u20131355 (2004).","journal-title":"Gastroenterology"},{"key":"BFnrd4050_CR6","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1002\/hep.20612","volume":"41","author":"M Reiser","year":"2005","unstructured":"Reiser, M. et al. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology 41, 832\u2013835 (2005).","journal-title":"Hepatology"},{"key":"BFnrd4050_CR7","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","volume":"364","author":"F Poordad","year":"2011","unstructured":"Poordad, F. et al. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364, 1195\u20131206 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrd4050_CR8","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","volume":"364","author":"BR Bacon","year":"2011","unstructured":"Bacon, B. R. et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 364, 1207\u20131217 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrd4050_CR9","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","volume":"364","author":"IM Jacobson","year":"2011","unstructured":"Jacobson, I. M. et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 364, 2405\u20132416 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrd4050_CR10","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","volume":"364","author":"S Zeuzem","year":"2011","unstructured":"Zeuzem, S. et al. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 364, 2417\u20132428 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrd4050_CR11","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1111\/j.1537-2995.2010.02622.x","volume":"50","author":"S Zou","year":"2010","unstructured":"Zou, S. et al. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion 50, 1495\u20131504 (2010).","journal-title":"Transfusion"},{"issue":"Suppl. 1","key":"BFnrd4050_CR12","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1093\/cid\/cis393","volume":"55","author":"RM Klevens","year":"2012","unstructured":"Klevens, R. M., Hu, D. J., Jiles, R. & Holmberg, S. D. Evolving epidemiology of hepatitis C virus in the United States. Clin. Infect. Dis. 55 (Suppl. 1), S3\u2013S9 (2012).","journal-title":"Clin. Infect. Dis."},{"key":"BFnrd4050_CR13","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1126\/science.277.5325.570","volume":"277","author":"AA Kolykhalov","year":"1997","unstructured":"Kolykhalov, A. A. et al. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 277, 570\u2013574 (1997).","journal-title":"Science"},{"key":"BFnrd4050_CR14","first-page":"71","volume":"3","author":"KJ Blight","year":"1998","unstructured":"Blight, K. J., Kolykhalov, A. A., Reed, K. E., Agapov, E. V. & Rice, C. M. Molecular virology of hepatitis C virus: an update with respect to potential antiviral targets. Antivir. Ther. 3, 71\u201381 (1998).","journal-title":"Antivir. Ther."},{"key":"BFnrd4050_CR15","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1126\/science.285.5424.110","volume":"285","author":"V Lohmann","year":"1999","unstructured":"Lohmann, V. et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285, 110\u2013113 (1999). First description of the HCV replicon system.","journal-title":"Science"},{"key":"BFnrd4050_CR16","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1073\/pnas.0511218103","volume":"103","author":"BD Lindenbach","year":"2006","unstructured":"Lindenbach, B. D. et al. Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc. Natl Acad. Sci. USA 103, 3805\u20133809 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd4050_CR17","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1053\/j.gastro.2008.05.044","volume":"135","author":"S Maylin","year":"2008","unstructured":"Maylin, S. et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 135, 821\u2013829 (2008).","journal-title":"Gastroenterology"},{"key":"BFnrd4050_CR18","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1053\/j.gastro.2010.07.009","volume":"139","author":"MG Swain","year":"2010","unstructured":"Swain, M. G. et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 139, 1593\u20131601 (2010).","journal-title":"Gastroenterology"},{"issue":"8","key":"BFnrd4050_CR19","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/jvh.12074","volume":"20","author":"M. P. Manns","year":"2013","unstructured":"Manns, M. P. et al. Long-term clearance of hepatitis C virus following interferon alfa-2b or peginterferon \u03b1-2b, alone or in combination with ribavirin. J. Viral Hepat. 3 Mar 2013 (doi:10.1111\/jvh.12074).","journal-title":"Journal of Viral Hepatitis"},{"key":"BFnrd4050_CR20","first-page":"569A","volume":"56","author":"T Pilot-Matias","year":"2012","unstructured":"Pilot-Matias, T. et al. Characterization of resistant variants in NS3 and NS5B detected in subjects treated with ABT-450\/r, ribavirin, and either ABT-072 or ABT-333 in the pilot and co-pilot studies who experienced virologic breakthrough or relapse. Hepatology 56, 569A\u2013570A (2012).","journal-title":"Hepatology"},{"key":"BFnrd4050_CR21","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1001\/jama.2012.144878","volume":"308","author":"AJ van der Meer","year":"2012","unstructured":"van der Meer, A. J. et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308, 2584\u20132593 (2012). First demonstration that SVR reduces overall mortality.","journal-title":"JAMA"},{"key":"BFnrd4050_CR22","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/hep.510240405","volume":"24","author":"T Poynard","year":"1996","unstructured":"Poynard, T. et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 24, 778\u2013789 (1996).","journal-title":"Hepatology"},{"key":"BFnrd4050_CR23","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","volume":"358","author":"MP Manns","year":"2001","unstructured":"Manns, M. P. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958\u2013965 (2001). First Phase III study to describe PEG-IFN\u03b1 in combination with ribavirin as a new standard of care from 2001 to 2011.","journal-title":"Lancet"},{"key":"BFnrd4050_CR24","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa020047","volume":"347","author":"MW Fried","year":"2002","unstructured":"Fried, M. W. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347, 975\u2013982 (2002).","journal-title":"N. Engl. J. Med."},{"key":"BFnrd4050_CR25","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/nm1268","volume":"11","author":"T Wakita","year":"2005","unstructured":"Wakita, T. et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nature Med. 11, 791\u2013796 (2005).","journal-title":"Nature Med."},{"key":"BFnrd4050_CR26","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1126\/science.1114016","volume":"309","author":"BD Lindenbach","year":"2005","unstructured":"Lindenbach, B. D. et al. Complete replication of hepatitis C virus in cell culture. Science 309, 623\u2013626 (2005).","journal-title":"Science"},{"key":"BFnrd4050_CR27","doi-asserted-by":"publisher","first-page":"9294","DOI":"10.1073\/pnas.0503596102","volume":"102","author":"J Zhong","year":"2005","unstructured":"Zhong, J. et al. Robust hepatitis C virus infection in vitro. Proc. Natl Acad. Sci. USA 102, 9294\u20139299 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd4050_CR28","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0092-8674(00)81350-1","volume":"87","author":"RA Love","year":"1996","unstructured":"Love, R. A. et al. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 87, 331\u2013342 (1996).","journal-title":"Cell"},{"key":"BFnrd4050_CR29","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S0092-8674(00)81351-3","volume":"87","author":"JL Kim","year":"1996","unstructured":"Kim, J. L. et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 87, 343\u2013355 (1996).","journal-title":"Cell"},{"key":"BFnrd4050_CR30","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/nature03580","volume":"435","author":"TL Tellinghuisen","year":"2005","unstructured":"Tellinghuisen, T. L., Marcotrigiano, J. & Rice, C. M. Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature 435, 374\u2013379 (2005).","journal-title":"Nature"},{"key":"BFnrd4050_CR31","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/13305","volume":"6","author":"CA Lesburg","year":"1999","unstructured":"Lesburg, C. A. et al. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nature Struct. Biol. 6, 937\u2013943 (1999).","journal-title":"Nature Struct. Biol."},{"key":"BFnrd4050_CR32","doi-asserted-by":"publisher","first-page":"13034","DOI":"10.1073\/pnas.96.23.13034","volume":"96","author":"S Bressanelli","year":"1999","unstructured":"Bressanelli, S. et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc. Natl Acad. Sci. USA 96, 13034\u201313039 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd4050_CR33","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0969-2126(00)80031-3","volume":"7","author":"H Ago","year":"1999","unstructured":"Ago, H. et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Structure 7, 1417\u20131426 (1999).","journal-title":"Structure"},{"key":"BFnrd4050_CR34","volume-title":"Fields Virology","author":"B Lindenbach","year":"2007","unstructured":"Lindenbach, B., Thiel, H. J. & Rice, C. M. in Fields Virology 5th edn (Lippincott-Raven, 2007)."},{"key":"BFnrd4050_CR35","doi-asserted-by":"publisher","first-page":"258","DOI":"10.4161\/rna.8.2.15011","volume":"8","author":"G Alvisi","year":"2011","unstructured":"Alvisi, G., Madan, V. & Bartenschlager, R. Hepatitis C virus and host cell lipids: an intimate connection. RNA Biol. 8, 258\u2013269 (2011).","journal-title":"RNA Biol."},{"key":"BFnrd4050_CR36","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.coviro.2011.12.007","volume":"2","author":"A Ploss","year":"2012","unstructured":"Ploss, A. & Evans, M. J. Hepatitis C virus host cell entry. Curr. Opin. Virol. 2, 14\u201319 (2012).","journal-title":"Curr. Opin. Virol."},{"key":"BFnrd4050_CR37","doi-asserted-by":"publisher","first-page":"e1003056","DOI":"10.1371\/journal.ppat.1003056","volume":"8","author":"I Romero-Brey","year":"2012","unstructured":"Romero-Brey, I. et al. Three-dimensional architecture and biogenesis of membrane structures associated with hepatitis C virus replication. PLoS Pathog. 8, e1003056 (2012).","journal-title":"PLoS Pathog."},{"key":"BFnrd4050_CR38","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/ng.453","volume":"41","author":"TR O'Brien","year":"2009","unstructured":"O'Brien, T. R. Interferon-alfa, interferon-lambda and hepatitis C. Nature Genet. 41, 1048\u20131050 (2009).","journal-title":"Nature Genet."},{"issue":"Suppl.","key":"BFnrd4050_CR39","first-page":"299A","volume":"56","author":"AJ Muir","year":"2012","unstructured":"Muir, A. J. et al. Peginterferon lambda-1a (Lambda) compared to Peginterferon alfa-2a (Alfa) in treatment-naive patients with HCV genotypes (GT) 1 or 4: SVR24. Results From EMERGE Phase 2b. Hepatology 56 (Suppl.), 299A (2012).","journal-title":"Hepatology"},{"issue":"Suppl. 2","key":"BFnrd4050_CR40","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/S0168-8278(12)60024-5","volume":"56","author":"S Zeuzem","year":"2012","unstructured":"Zeuzem, S. et al. Peginterferon lambda-1a (Lambda) compared to Peginterferon alfa-2a (Alfa) in treatment-naive patients with HCV genotypes (G) 2 or 3: first SVR24 results from EMERGE Phase IIB. J. Hepatol. 56 (Suppl. 2), S5\u2013S6 (2012).","journal-title":"J. Hepatol."},{"key":"BFnrd4050_CR41","doi-asserted-by":"publisher","first-page":"R488","DOI":"10.1016\/j.cub.2011.05.039","volume":"21","author":"EM Moresco","year":"2011","unstructured":"Moresco, E. M., LaVine, D. & Beutler, B. Toll-like receptors. Curr. Biol. 21, R488\u2013R493 (2011).","journal-title":"Curr. Biol."},{"key":"BFnrd4050_CR42","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1038\/nature04975","volume":"442","author":"IC Lorenz","year":"2006","unstructured":"Lorenz, I. C., Marcotrigiano, J., Dentzer, T. G. & Rice, C. M. Structure of the catalytic domain of the hepatitis C virus NS2-3 protease. Nature 442, 831\u2013835 (2006).","journal-title":"Nature"},{"key":"BFnrd4050_CR43","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1053\/j.gastro.2009.11.055","volume":"138","author":"C Sarrazin","year":"2010","unstructured":"Sarrazin, C. & Zeuzem, S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 138, 447\u2013462 (2010).","journal-title":"Gastroenterology"},{"key":"BFnrd4050_CR44","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1128\/AAC.01598-08","volume":"53","author":"MF McCown","year":"2009","unstructured":"McCown, M. F., Rajyaguru, S., Kular, S., Cammack, N. & Najera, I. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. Antimicrob. Agents Chemother. 53, 2129\u20132132 (2009).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrd4050_CR45","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.cld.2011.05.014","volume":"15","author":"S Ciesek","year":"2011","unstructured":"Ciesek, S., von Hahn, T. & Manns, M. P. Second-wave protease inhibitors: choosing an heir. Clin. Liver Dis. 15, 597\u2013609 (2011).","journal-title":"Clin. Liver Dis."},{"issue":"Suppl. 1","key":"BFnrd4050_CR46","doi-asserted-by":"publisher","first-page":"S568","DOI":"10.1016\/S0168-8278(13)61412-9","volume":"58","author":"M Manns","year":"2013","unstructured":"Manns, M. et al. Simeprevir (TMC435) with peginterferon\/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-2, a Phase III trial. J. Hepatol. 58 (Suppl. 1), S568 (2013).","journal-title":"J. Hepatol."},{"issue":"Suppl. 1","key":"BFnrd4050_CR47","doi-asserted-by":"publisher","first-page":"S574","DOI":"10.1016\/S0168-8278(13)61424-5","volume":"58","author":"I Jacobson","year":"2013","unstructured":"Jacobson, I. et al. Simeprevir (TMC435) with peginterferon\/ribavirin for chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-1, a Phase III trial. J. Hepatol. 58 (Suppl. 1), S574 (2013).","journal-title":"J. Hepatol."},{"issue":"6","key":"BFnrd4050_CR48","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1002\/hep.26276","volume":"57","author":"Mark S. Sulkowski","year":"2013","unstructured":"Sulkowski, M. S. et al. Faldaprevir combined with peginterferon alfa-2a and ribavirin in treatment-naive patients with chronic genotype-1 HCV: SILEN-C1 trial. Hepatology 28 Jan 2013 (doi: 10.1002\/hep.26276).","journal-title":"Hepatology"},{"issue":"6","key":"BFnrd4050_CR49","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1002\/hep.26386","volume":"57","author":"Mark S. Sulkowski","year":"2013","unstructured":"Sulkowski, M. S. et al. Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic HCV genotype-1 patients with prior nonresponse: SILEN-C2 trial. Hepatology 15 Mar 2013 (doi:10.1002\/hep.26386).","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"BFnrd4050_CR50","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/S0168-8278(13)60068-9","volume":"58","author":"M Manns","year":"2013","unstructured":"Manns, M. et al. High sustained viral response at 12- and 24-week follow-up of MK-5172 with pegylated interferon alfa-2b and ribavirin (PR) in HCV genotype 1 treatment-naive non-cirrhotic patients. J. Hepatol. 58 (Suppl. 1), S30 (2013).","journal-title":"J. Hepatol."},{"key":"BFnrd4050_CR51","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3851\/IMP2088","volume":"17","author":"JM Pawlotsky","year":"2012","unstructured":"Pawlotsky, J. M., Najera, I. & Jacobson, I. Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase. Antivir. Ther. 17, 411\u2013423 (2012).","journal-title":"Antivir. Ther."},{"key":"BFnrd4050_CR52","unstructured":"Bristol-Myers Squibb. Press release 23 Aug 2012: Bristol-Myers Squibb discontinues development of BMS-986094, an investigational NS5B nucleotide for the treatment of hepatitis C. BMS website[online], (2012)."},{"key":"BFnrd4050_CR53","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","volume":"368","author":"E Lawitz","year":"2013","unstructured":"Lawitz, E. et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N. Engl. J. Med. 368, 1878\u20131887 (2013). Phase II data on sofosbuvir in all genotypes from the NEUTRINO and FISSION studies.","journal-title":"N. Engl. J. Med."},{"issue":"Suppl.","key":"BFnrd4050_CR54","first-page":"572A","volume":"56","author":"GT Everson","year":"2012","unstructured":"Everson, G. T. et al. The NS5A inhibitor GS-5885 is safe and well-tolerated in over 1000 patients treated in Phase 2 studies. Hepatology 56 (Suppl.), 572A\u2013573A (2012).","journal-title":"Hepatology"},{"issue":"Suppl.","key":"BFnrd4050_CR55","first-page":"1516A","volume":"56","author":"MS Sulkowski","year":"2012","unstructured":"Sulkowski, M. S. et al. High rate of sustained virologic response with the all-oral combination of daclatasvir (NS5A inhibitor) plus sofosbuvir (nucleotide NS5B inhibitor), with or without ribavirin, in treatment-naive patients chronically Infected with HCV genotype 1, 2, or 3. Hepatology, 56 (Suppl.), 1516A\u20131517A (2012).","journal-title":"Hepatology"},{"issue":"Suppl. 2","key":"BFnrd4050_CR56","doi-asserted-by":"publisher","first-page":"S478","DOI":"10.1016\/S0168-8278(12)61218-5","volume":"56","author":"F Poordad","year":"2012","unstructured":"Poordad, F. et al. ABT-072 or ABT-333 combined with pegylated interferon\/ribavirin after 3-day monotherapy in HCV genotype 1 (GT1)-infected treatment-naive subjects: 12-week sustained virologic response (SVR12) and safety results. J. Hepatol. 56 (Suppl. 2), S478 (2012).","journal-title":"J. Hepatol."},{"key":"BFnrd4050_CR57","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1073\/pnas.1203110110","volume":"110","author":"J Guedj","year":"2013","unstructured":"Guedj, J. et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc. Natl Acad. Sci. USA 110, 3991\u20133996 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd4050_CR58","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature08960","volume":"465","author":"M Gao","year":"2010","unstructured":"Gao, M. et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465, 96\u2013100 (2010).","journal-title":"Nature"},{"issue":"Suppl.","key":"BFnrd4050_CR59","first-page":"553A","volume":"56","author":"C H\u00e9zode","year":"2012","unstructured":"H\u00e9zode, C. et al. Daclatasvir, an NS5A replication complex inhibitor, combined With Peginterferon alfa-2a & ribavirin in treatment-naive, HCV-genotype 1 or 4 subjects: Phase 2b COMMAND-1 SVR12 results. Hepatology 56 (Suppl.), 553A\u2013554A (2012).","journal-title":"Hepatology"},{"key":"BFnrd4050_CR60","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1002\/hep.24594","volume":"54","author":"RA Fridell","year":"2011","unstructured":"Fridell, R. A. et al. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology 54, 1924\u20131935 (2011).","journal-title":"Hepatology"},{"issue":"Suppl.","key":"BFnrd4050_CR61","first-page":"230A","volume":"56","author":"AS Lok","year":"2012","unstructured":"Lok, A. S. et al. Sustained virologic response in chronic HCV genotype (GT) 1-Infected null responders with combination of daclatasvir (DCV; NS5A inhibitor) and asunaprevir (ASV; NS3 Inhibitor) with or without Peginterferon alfa-2a\/ribavirin (PEG\/RBV). Hepatology 56 (Suppl.), 230A\u2013231A (2012).","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"BFnrd4050_CR62","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1016\/S0168-8278(13)60066-5","volume":"58","author":"A Thompson","year":"2013","unstructured":"Thompson, A. et al. GS-5885 + GS-9451 + peginterferon and ribavirin (PR) for six or twelve weeks achieves high SVR12 rates in treatment-naive genotype 1 IL28B CC patients. J. Hepatol. 58 (Suppl. 1), S29 (2013).","journal-title":"J. Hepatol."},{"key":"BFnrd4050_CR63","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1038\/nbt.1490","volume":"26","author":"S Einav","year":"2008","unstructured":"Einav, S. et al. Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis. Nature Biotech. 26, 1019\u20131027 (2008).","journal-title":"Nature Biotech."},{"key":"BFnrd4050_CR64","first-page":"237","volume":"12","author":"T von Hahn","year":"2011","unstructured":"von Hahn, T., Ciesek, S. & Manns, M. P. Arrest all accessories \u2014 inhibition of hepatitis C virus by compounds that target host factors. Discov. Med. 12, 237\u2013244 (2011).","journal-title":"Discov. Med."},{"key":"BFnrd4050_CR65","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/hep.21102","volume":"43","author":"J Paeshuyse","year":"2006","unstructured":"Paeshuyse, J. et al. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 43, 761\u2013770 (2006).","journal-title":"Hepatology"},{"key":"BFnrd4050_CR66","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/hep.24610","volume":"54","author":"S Ciesek","year":"2011","unstructured":"Ciesek, S. et al. The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. Hepatology 54, 1947\u20131955 (2011).","journal-title":"Hepatology"},{"key":"BFnrd4050_CR67","doi-asserted-by":"publisher","first-page":"12616","DOI":"10.1128\/JVI.01351-12","volume":"86","author":"A Nag","year":"2012","unstructured":"Nag, A., Robotham, J. M. & Tang, H. Suppression of viral RNA binding and the assembly of infectious hepatitis C virus particles in vitro by cyclophilin inhibitors. J. Virol. 86, 12616\u201312624 (2012).","journal-title":"J. Virol."},{"key":"BFnrd4050_CR68","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1002\/hep.22835","volume":"49","author":"R Flisiak","year":"2009","unstructured":"Flisiak, R. et al. The cyclophilin inhibitor Debio 025 combined with PEG IFN\u03b12a significantly reduces viral load in treatment-naive hepatitis C patients. Hepatology 49, 1460\u20131468 (2009).","journal-title":"Hepatology"},{"issue":"Suppl.","key":"BFnrd4050_CR69","first-page":"309A","volume":"56","author":"J-M Pawlotsky","year":"2012","unstructured":"Pawlotsky, J.-M. et al. Alisporivir plus ribavirin achieves high rates of sustained HCV clearance (SVR24) as interferon (IFN)-free or IFN-add-on regimen in treatment-naive patients with HCV GT2 or GT3: final results from VITAL-1 study. Hepatology 56 (Suppl.), 309A\u2013310A (2012).","journal-title":"Hepatology"},{"key":"BFnrd4050_CR70","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1136\/gut.2010.217323","volume":"60","author":"H Patel","year":"2011","unstructured":"Patel, H. & Heathcote, E. J. Sustained virological response with 29 days of Debio 025 monotherapy in hepatitis C virus genotype 3. Gut 60, 879 (2011).","journal-title":"Gut"},{"key":"BFnrd4050_CR71","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1126\/science.1178178","volume":"327","author":"RE Lanford","year":"2010","unstructured":"Lanford, R. E. et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327, 198\u2013201 (2010).","journal-title":"Science"},{"key":"BFnrd4050_CR72","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1083\/jcb.201208082","volume":"199","author":"M Lindow","year":"2012","unstructured":"Lindow, M. & Kauppinen, S. Discovering the first microRNA-targeted drug. J. Cell Biol. 199, 407\u2013412 (2012).","journal-title":"J. Cell Biol."},{"key":"BFnrd4050_CR73","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMoa1209026","volume":"368","author":"HL Janssen","year":"2013","unstructured":"Janssen, H. L. et al. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 368, 1685\u20131694 (2013). First study to describe efficacy of an miRNA-directed treatment in humans.","journal-title":"N. Engl. J. Med."},{"key":"BFnrd4050_CR74","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jhep.2010.06.024","volume":"54","author":"AJ Syder","year":"2011","unstructured":"Syder, A. J. et al. Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. J. Hepatol. 54, 48\u201355 (2011).","journal-title":"J. Hepatol."},{"key":"BFnrd4050_CR75","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1056\/NEJMoa1104430","volume":"366","author":"AS Lok","year":"2012","unstructured":"Lok, A. S. et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N. Engl. J. Med. 366, 216\u2013224 (2012). Proof of concept that SVR can be achieved with an all-oral DAA combination.","journal-title":"N. Engl. J. Med."},{"key":"BFnrd4050_CR76","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/hep.24724","volume":"55","author":"K Chayama","year":"2012","unstructured":"Chayama, K. et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 55, 742\u2013748 (2012).","journal-title":"Hepatology"},{"key":"BFnrd4050_CR77","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1208809","volume":"368","author":"F Poordad","year":"2013","unstructured":"Poordad, F. et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N. Engl. J. Med. 368, 45\u201353 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnrd4050_CR78","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/hep.24744","volume":"55","author":"S Zeuzem","year":"2012","unstructured":"Zeuzem, S. et al. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology 55, 749\u2013758 (2012).","journal-title":"Hepatology"},{"issue":"Suppl.","key":"BFnrd4050_CR79","first-page":"1515A","volume":"56","author":"KV Kowdley","year":"2012","unstructured":"Kowdley, K. V. et al. A 12-week interferon-free treatment regimen with ABT-450\/r, ABT-267, ABT-333 and ribavirin achieves SVR rates (observed data) of 99% in treatment-naive patients and 93% in prior null responders with HCV genotype 1 infection. Hepatology 56 (Suppl.), 1515A\u20131516A (2012).","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"BFnrd4050_CR80","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/S0168-8278(13)60005-7","volume":"58","author":"KV Kowdley","year":"2013","unstructured":"Kowdley, K. V. et al. Safety & efficacy of interferon-free regimens of ABT-450\/r, ABT-267, ABT-333 +\/\u2212 ribavirin in patients with chronic HCV GT1 infection: results from the AVIATOR study. J. Hepatol. 58 (Suppl. 1), S2 (2013).","journal-title":"J. Hepatol."},{"issue":"Suppl. 1","key":"BFnrd4050_CR81","doi-asserted-by":"publisher","first-page":"S570","DOI":"10.1016\/S0168-8278(13)61416-6","volume":"58","author":"MS Sulkowski","year":"2013","unstructured":"Sulkowski, M. S. et al. Sustained virologic response with daclatasvir plus sofosbuvir \u00b1 ribavirin (RBV) in chronic HCV genotype (GT) 1-infected patients who previously failed telaprevir (TVR) or boceprevir (BOC). J. Hepatol. 58 (Suppl. 1), S570 (2013).","journal-title":"J. Hepatol."},{"issue":"6","key":"BFnrd4050_CR82","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1111\/ajt.12209","volume":"13","author":"R. J. Fontana","year":"2013","unstructured":"Fontana, R. J. et al. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am. J. Transplant. 17 Apr 2013 (doi:10.1111\/ajt.12209). Demonstration that an all-oral DAA combination can be used in post-transplantation cholestatic hepatitis.","journal-title":"American Journal of Transplantation"},{"key":"BFnrd4050_CR83","doi-asserted-by":"crossref","unstructured":"Lawitz, E. et al. Suppression of viral load through 4 weeks post-treatment results of a once-daily regimen of simeprevir + sofosbuvir with or without ribavirin in hepatitis C virus GT 1 null responders. Conference on Retroviruses and Opportunistic Infections website[online], (2013).","DOI":"10.1016\/S0016-5085(13)61382-7"},{"issue":"Suppl. 1","key":"BFnrd4050_CR84","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/S0168-8278(13)60007-0","volume":"58","author":"E Gane","year":"2013","unstructured":"Gane, E. et al. Phase 3 randomized controlled trial of all-oral treatment with sofosbuvir + ribavirin for 12 weeks compared to 24 weeks of peg + ribavirin in treatment-naive GT 2\/3 HCV-infected patients (FISSION). J. Hepatol. 58 (Suppl. 1), S3 (2013).","journal-title":"J. Hepatol."},{"key":"BFnrd4050_CR85","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","volume":"368","author":"IM Jacobson","year":"2013","unstructured":"Jacobson, I. M. et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N. Engl. J. Med. 368, 1867\u20131877 (2013). Phase III data on sofosbuvir in genotypes 2\/3.","journal-title":"N. Engl. J. Med."},{"issue":"Suppl.","key":"BFnrd4050_CR86","first-page":"569A","volume":"56","author":"S Zeuzem","year":"2012","unstructured":"Zeuzem, S. et al. SOUND-C2: SVR4, 12 & 24 concordance in genotype (GT) 1 HCV. patients receiving interferon (IFN)-free treatment with the HCV NS3\/4A protease inhibitor BI 201335 & the NS5B polymerase inhibitor B I 207127. Hepatology 56 (Suppl.), 569A (2012).","journal-title":"Hepatology"},{"issue":"Suppl.","key":"BFnrd4050_CR87","first-page":"234A","volume":"56","author":"V Soriano","year":"2012","unstructured":"Soriano, V. et al. Efficacy and safety of the interferon (IFN)-free combination of BI 201335 + BI 207127 \u00b1ribavirin (RBV) in treatment-naive patients with HCV genotype (GT) 1 infection and compensated liver cirrhosis: Results from the SOUND-C2 study. Hepatology 56 (Suppl.), 234A (2012).","journal-title":"Hepatology"},{"issue":"Suppl.","key":"BFnrd4050_CR88","first-page":"1517A","volume":"56","author":"GT Everson","year":"2012","unstructured":"Everson, G. T. et al. An interferon-free, ribavirin-free 12-week regimen of daclatasvir (DCV), asunaprevir (ASV), and BMS-791325 yielded SVR4 of 94% in treatment-naive patients with genotype (GT) 1 chronic hepatitis C virus (HCV) infection. Hepatology 56 (Suppl.), 1517A\u20131518A (2012).","journal-title":"Hepatology"},{"issue":"Suppl.","key":"BFnrd4050_CR89","first-page":"268A","volume":"56","author":"B Pearlman","year":"2012","unstructured":"Pearlman, B. et al. Hepatitis C virus (HCV) genotype 1 (G1) infection with low viral load (LVL) and rapid virologic response (RVR) to peginterferon and ribavirin (PEG\/RBV) can be treated without a protease inhibitor (PI), irrespective of IL-28B status or patient ethnicity. Hepatology 56 (Suppl.), 268A (2012).","journal-title":"Hepatology"},{"key":"BFnrd4050_CR90","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1002\/hep.25734","volume":"56","author":"C Camma","year":"2012","unstructured":"Camma, C. et al. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology 56, 850\u2013860 (2012).","journal-title":"Hepatology"},{"key":"BFnrd4050_CR91","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1002\/hep.23220","volume":"50","author":"ML Volk","year":"2009","unstructured":"Volk, M. L., Tocco, R., Saini, S. & Lok, A. S. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 50, 1750\u20131755 (2009).","journal-title":"Hepatology"},{"key":"BFnrd4050_CR92","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1053\/j.gastro.2012.02.011","volume":"142","author":"G Crespo","year":"2012","unstructured":"Crespo, G., Marino, Z., Navasa, M. & Forns, X. Viral hepatitis in liver transplantation. Gastroenterology 142, 1373\u20131383.e1 (2012).","journal-title":"Gastroenterology"},{"key":"BFnrd4050_CR93","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1002\/hep.20819","volume":"42","author":"P Simmonds","year":"2005","unstructured":"Simmonds, P. et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42, 962\u2013973 (2005).","journal-title":"Hepatology"},{"key":"BFnrd4050_CR94","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1099\/vir.0.80401-0","volume":"85","author":"P Simmonds","year":"2004","unstructured":"Simmonds, P. Genetic diversity and evolution of hepatitis C virus \u2014 15 years on. J. Gen. Virol. 85, 3173\u20133188 (2004).","journal-title":"J. Gen. Virol."},{"key":"BFnrd4050_CR95","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1055\/s-0031-1297925","volume":"31","author":"P Farci","year":"2011","unstructured":"Farci, P. New insights into the HCV quasispecies and compartmentalization. Semin. Liver Dis. 31, 356\u2013374 (2011).","journal-title":"Semin. Liver Dis."},{"key":"BFnrd4050_CR96","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/j.1365-2893.2011.01481.x","volume":"18","author":"A Probst","year":"2011","unstructured":"Probst, A. et al. Role of hepatitis C virus genotype 3 in liver fibrosis progression \u2014 a systematic review and meta-analysis. J. Viral Hepat. 18, 745\u2013759 (2011).","journal-title":"J. Viral Hepat."},{"issue":"Suppl. 1","key":"BFnrd4050_CR97","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/j.1478-3231.2011.02715.x","volume":"32","author":"SK Sarin","year":"2012","unstructured":"Sarin, S. K. & Kumar, C. K. Treatment of patients with genotype 3 chronic hepatitis C \u2014 current and future therapies. Liver Int. 32 (Suppl. 1), 141\u2013145 (2012).","journal-title":"Liver Int."},{"key":"BFnrd4050_CR98","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/ng.2521","volume":"45","author":"L Prokunina-Olsson","year":"2013","unstructured":"Prokunina-Olsson, L. et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nature Genet. 45, 164\u2013171 (2013). Describes a pkossible mechanism behind the  IL28B  variant.","journal-title":"Nature Genet."},{"key":"BFnrd4050_CR99","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nature08309","volume":"461","author":"D Ge","year":"2009","unstructured":"Ge, D. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461, 399\u2013401 (2009).","journal-title":"Nature"},{"key":"BFnrd4050_CR100","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1126\/science.1097670","volume":"305","author":"SI Khakoo","year":"2004","unstructured":"Khakoo, S. I. et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305, 872\u2013874 (2004).","journal-title":"Science"},{"key":"BFnrd4050_CR101","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nature08825","volume":"464","author":"J Fellay","year":"2010","unstructured":"Fellay, J. et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 464, 405\u2013408 (2010).","journal-title":"Nature"},{"key":"BFnrd4050_CR102","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1053\/j.gastro.2010.06.071","volume":"139","author":"H Ochi","year":"2010","unstructured":"Ochi, H. et al. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy \u2014 a genome-wide study of Japanese HCV virus patients. Gastroenterology 139, 1190\u20131197 (2010).","journal-title":"Gastroenterology"},{"key":"BFnrd4050_CR103","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/hep.24123","volume":"53","author":"L Valenti","year":"2011","unstructured":"Valenti, L. et al. Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology 53, 791\u2013799 (2011).","journal-title":"Hepatology"},{"key":"BFnrd4050_CR104","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1002\/hep.25848","volume":"56","author":"E Falleti","year":"2012","unstructured":"Falleti, E. et al. Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C. Hepatology 56, 1641\u20131650 (2012).","journal-title":"Hepatology"},{"key":"BFnrd4050_CR105","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.jhep.2010.08.036","volume":"54","author":"CM Lange","year":"2011","unstructured":"Lange, C. M. et al. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J. Hepatol. 54, 887\u2013893 (2011).","journal-title":"J. Hepatol."},{"key":"BFnrd4050_CR106","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1002\/hep.26190","volume":"57","author":"S Westhaus","year":"2012","unstructured":"Westhaus, S. et al. Characterization of the inhibition of hepatitis C virus entry by in vitro-generated and patient-derived oxidized low-density lipoprotein. Hepatology 57, 1716\u20131724 (2012).","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"BFnrd4050_CR107","doi-asserted-by":"publisher","first-page":"i36","DOI":"10.1136\/gutjnl-2012-302144","volume":"61","author":"C Welsch","year":"2012","unstructured":"Welsch, C., Jesudian, A., Zeuzem, S. & Jacobson, I. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut 61 (Suppl. 1), i36\u2013i46 (2012).","journal-title":"Gut"},{"issue":"Suppl. 2","key":"BFnrd4050_CR108","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/S0168-8278(12)60022-1","volume":"56","author":"C H\u00e9zode","year":"2012","unstructured":"H\u00e9zode, C. et al. Safety of telaprevir or boceprevir in combination with peginterferon alfa\/ribavirin, in cirrhotic non responders. First results of the French early access program (Anrs C020-Cupic). J. Hepatol. 56 (Suppl. 2), S4 (2012).","journal-title":"J. Hepatol."},{"issue":"Suppl. 1","key":"BFnrd4050_CR109","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/S0168-8278(13)60067-7","volume":"58","author":"K Rutter","year":"2013","unstructured":"Rutter, K. et al. Safety of triple therapy with telaprevir or boceprevir in hepatitis C patients with advanced liver disease \u2014 predictive factors for sepsis. J. Hepatol. 58 (Suppl. 1), S30 (2013).","journal-title":"J. Hepatol."},{"issue":"Suppl. 1","key":"BFnrd4050_CR110","first-page":"1037A","volume":"56","author":"S Mauss","year":"2013","unstructured":"Mauss, S. et al. Safety & week 4\/12 HCV RNA results of triple combination with telaprevir (TVR)\/peginterferon alfa-2a (P)\/ribavirin (R), in F3\/F4 patients in real-life setting. Hepatology 56 (Suppl. 1), 1037A (2013).","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"BFnrd4050_CR111","first-page":"1044A","volume":"56","author":"K Bichoupan","year":"2013","unstructured":"Bichoupan, K. Real world effectiveness of telaprevir-based triple therapy: lower on-treatment virological responses than in RCTs. Hepatology 56 (Suppl. 1), 1044A (2013).","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"BFnrd4050_CR112","doi-asserted-by":"publisher","first-page":"S576","DOI":"10.1016\/S0168-8278(13)61429-4","volume":"58","author":"JM Vierling","year":"2013","unstructured":"Vierling, J. M. et al. Safety and efficacy of boceprevir\/peginterferon\/ ribavirin (BOC\/P\/R) combination therapy for chronic HCV g1 patients with compensated cirrhosis: a meta-analysis of five Phase 3 clinical trials. J. Hepatol. 58 (Suppl. 1), S576\u2013S577 (2013).","journal-title":"J. Hepatol."},{"issue":"Suppl. 1","key":"BFnrd4050_CR113","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1016\/S0168-8278(13)60062-8","volume":"58","author":"H Fontaine","year":"2013","unstructured":"Fontaine, H. et al. SVR12 rates and safety of triple therapy including telaprevir or boceprevir in 221 cirrhotic non responders treated in the French early access program (ANRS CO20-CUPIC). J. Hepatol. 58 (Suppl. 1), S27 (2013).","journal-title":"J. Hepatol."},{"issue":"Suppl. 1","key":"BFnrd4050_CR114","first-page":"218A","volume":"56","author":"EC Verna","year":"2013","unstructured":"Verna, E. C. et al. High early response rates with protease inhibitor triple therapy in a multicenter cohort of HCV-infected patients awaiting liver transplantation. Hepatology 56 (Suppl. 1), 218A (2013).","journal-title":"Hepatology"},{"key":"BFnrd4050_CR115","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1053\/j.gastro.2007.02.037","volume":"132","author":"C Sarrazin","year":"2007","unstructured":"Sarrazin, C. et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132, 1767\u20131777 (2007).","journal-title":"Gastroenterology"},{"key":"BFnrd4050_CR116","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1002\/hep.23192","volume":"50","author":"S Susser","year":"2009","unstructured":"Susser, S. et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 50, 1709\u20131718 (2009).","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"BFnrd4050_CR117","doi-asserted-by":"publisher","first-page":"S326","DOI":"10.1016\/S0168-8278(13)60800-4","volume":"58","author":"M Buti","year":"2013","unstructured":"Buti, M. et al. Efficacy of telaprevir dosed twice daily versus every 8 hours by IL28B genotype: results from the Phase III OPTIMIZE study. J. Hepatol. 58 (Suppl. 1), S326 (2013).","journal-title":"J. Hepatol."},{"issue":"Suppl. 1","key":"BFnrd4050_CR118","doi-asserted-by":"publisher","first-page":"S362","DOI":"10.1016\/S0168-8278(13)60883-1","volume":"58","author":"DR Nelson","year":"2013","unstructured":"Nelson, D. R. et al. High SVR rates (SVR4) for 12-week total telaprevir combination therapy in IL28B CC treatment-naives and prior relapsers with g1 chronic hepatitis C: concise interim analysis. J. Hepatol. 58 (Suppl. 1), S362 (2013).","journal-title":"J. Hepatol."},{"key":"BFnrd4050_CR119","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMra1200391","volume":"368","author":"DR Hopkins","year":"2013","unstructured":"Hopkins, D. R. Disease eradication. N. Engl. J. Med. 368, 54\u201363 (2013).","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"BFnrd4050_CR120","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1002\/hep.26218","volume":"57","author":"Homie Razavi","year":"2013","unstructured":"Razavi, H. et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology 22 Dec 2012 (doi:10.1002\/hep.26218).","journal-title":"Hepatology"},{"key":"BFnrd4050_CR121","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1056\/NEJM198911303212202","volume":"321","author":"HJ Alter","year":"1989","unstructured":"Alter, H. J. et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N. Engl. J. Med. 321, 1494\u20131500 (1989).","journal-title":"N. Engl. J. Med."},{"key":"BFnrd4050_CR122","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1126\/science.2496467","volume":"244","author":"G Kuo","year":"1989","unstructured":"Kuo, G. et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 244, 362\u2013364 (1989).","journal-title":"Science"},{"key":"BFnrd4050_CR123","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/S0140-6736(98)07124-4","volume":"352","author":"T Poynard","year":"1998","unstructured":"Poynard, T. et al. Randomised trial of interferon \u03b12b plus ribavirin for 48 weeks or for 24 weeks versus interferon \u03b12b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352, 1426\u20131432 (1998).","journal-title":"Lancet"},{"key":"BFnrd4050_CR124","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1056\/NEJM198911303212203","volume":"321","author":"GL Davis","year":"1989","unstructured":"Davis, G. L. et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 321, 1501\u20131506 (1989).","journal-title":"N. Engl. J. Med."},{"key":"BFnrd4050_CR125","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1056\/NEJM199506013322201","volume":"332","author":"T Poynard","year":"1995","unstructured":"Poynard, T. et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N. Engl. J. Med. 332, 1457\u20131462 (1995).","journal-title":"N. Engl. J. Med."},{"key":"BFnrd4050_CR126","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","volume":"339","author":"JG McHutchison","year":"1998","unstructured":"McHutchison, J. G. et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339, 1485\u20131492 (1998).","journal-title":"N. Engl. J. Med."},{"key":"BFnrd4050_CR127","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1056\/NEJM200012073432301","volume":"343","author":"S Zeuzem","year":"2000","unstructured":"Zeuzem, S. et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N. Engl. J. Med. 343, 1666\u20131672 (2000).","journal-title":"N. Engl. J. Med."},{"key":"BFnrd4050_CR128","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1053\/jhep.2001.26371","volume":"34","author":"KL Lindsay","year":"2001","unstructured":"Lindsay, K. L. et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 34, 395\u2013403 (2001).","journal-title":"Hepatology"},{"key":"BFnrd4050_CR129","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1111\/j.1572-0241.2004.30306.x","volume":"99","author":"PJ Pockros","year":"2004","unstructured":"Pockros, P. J. et al. Efficacy and safety of two-dose regimens of peginterferon \u03b1-2a compared with interferon \u03b1-2a in chronic hepatitis C: a multicenter, randomized controlled trial. Am. J. Gastroenterol. 99, 1298\u20131305 (2004).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrd4050_CR130","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/ng.447","volume":"41","author":"V Suppiah","year":"2009","unstructured":"Suppiah, V. et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nature Genet. 41, 1100\u20131104 (2009).","journal-title":"Nature Genet."},{"key":"BFnrd4050_CR131","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/ng.449","volume":"41","author":"Y Tanaka","year":"2009","unstructured":"Tanaka, Y. et al. Genome-wide association of IL28B with response to pegylated interferon-\u03b1 and ribavirin therapy for chronic hepatitis C. Nature Genet. 41, 1105\u20131109 (2009).","journal-title":"Nature Genet."},{"key":"BFnrd4050_CR132","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jhep.2012.09.037","volume":"58","author":"Y Suzuki","year":"2013","unstructured":"Suzuki, Y. et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J. Hepatol. 58, 655\u2013662 (2013).","journal-title":"J. Hepatol."}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nrd4050.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrd4050","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrd4050.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T17:29:56Z","timestamp":1684862996000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrd4050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,28]]},"references-count":132,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["BFnrd4050"],"URL":"https:\/\/doi.org\/10.1038\/nrd4050","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,28]]},"assertion":[{"value":"28 June 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.P.M has received fees for consulting work and\/or for giving lectures from Roche, Bristol-Myers Squibb, Gilead, Boehringer Ingelheim, Novartis, Merck, Janssen, GlaxoSmithKline, Idenix and Achillion. He has also received research grants from Roche, Gilead, Novartis, Boehringer Ingelheim, Bristol-Myers Squibb, Merck and Janssen. T.v.H. has received speaker's fees from Bristol-Myers Squibb, Merck Sharp & Dohme, and research funding from Novartis and Roche.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}